HUE028594T2 - Cardiovascularis betegség diagnózisa - Google Patents

Cardiovascularis betegség diagnózisa Download PDF

Info

Publication number
HUE028594T2
HUE028594T2 HUE12152464A HUE12152464A HUE028594T2 HU E028594 T2 HUE028594 T2 HU E028594T2 HU E12152464 A HUE12152464 A HU E12152464A HU E12152464 A HUE12152464 A HU E12152464A HU E028594 T2 HUE028594 T2 HU E028594T2
Authority
HU
Hungary
Prior art keywords
subject
level
bnp
levels
bmi
Prior art date
Application number
HUE12152464A
Other languages
English (en)
Inventor
James V Snider
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of HUE028594T2 publication Critical patent/HUE028594T2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (5)

  1. SZABÁSA LMÍ IGÉN V PONTOK 1. 7« vitro éprás cárdiovasoolads betegség tCVÖj diagnosztizálására alanyban, a7cîï#|; tsd^beg Ittbésé (8MÍ) pagyobb vagy egyen!« |$-séS. vagy károsodott vesefunkciója vsa, gltti az e|Äi tartalmazza: az alany testtömeg indexének (BMÎ) kiválasztását ésijta az álasy BMSide nagyobb vagy «gyeseié 2S-tsél, m alany kíválasztássk vsgy az alany vasefenkdé|áasfc értékelését és na M alanynak károsodott Yesa:pifeiója vsa, áli$r az alany y választását; és: Bttlpaá pítóörstíkaá g$p(ü (BM*> Is itteftebkín 1 mesgttoNszerf I pT2) megPtátöziSÉis kiválasztott: slatty biótogia! onntálában: afeo! az alany BNP szltti|d Is Oldható ST2 szsnfe Riaħ&, bogy m alanynak van-e C¥D-ja.
  2. 2. Az I. Igénypont &zennf elárás, alól a CVD szlvellgíelttttssg: va^- tSdpmhöMa, iá, Az 1. ;igéöy|ttttlt;SkéfiÉI d||rás, sittől az alpynak dpgsoep vagy meM&pakm van,
  3. 4, Az 1. Igêbypont szeriatt e|árág, api m oÄato MB szintje meg van határozva rendelkezésre álláskofs vagy lyf nappai a sadist féllépte mánmalanyóam
  4. 5. Az I, igénypont szerinti ejjáráa, amely iovabêâ íam&nazza az alanyban agy vagy iösh másik biomarker szint megpíározasát, amelyek opcionálisan. ki vasnak válaszig a következőkből álló éSöpottbói: 'N-vegő pto-aînalls saídatadkas pepiM fjNTkproANP), atdails: saMarettkas pepiid jANF). irnfSSÄ, C-reaktlv :PeÄfei». vdir ifcaÖKsmM nitrogén éBíTMk nïâj&mkeiè enzimek, albtsnm. és bakteriális endotoxin. & Az t, igénypont szerinti. eljárás, apt annák. tóeglsíttározása, bogy az alanynak vanm káensodott veseörnkelöilk lartalrnazm a glnamralám fttrádós ssbesség (GFR) éSÁagy széf«® kröätiÄ színi: megbáiároa&Sát és az alanynak károsodott yesaípkeicp van. ka GFR-jPk vagy sz^aíni kZsálíbsn iSzfeijttk a kövéikezö .táblázat szerinti:
    %. Az 1. igénypont szerinti eljárás, Sböl az alanynak károsodott y«sefonk.dójs van,, lia GFR-jSk kisebb, mnl 50 ujjperc».
  5. 8.. Az I. igénypont szedőit éjjálás, ahol az alanynak ΒΚΒφ nagyobb vagy egyenlő PMïâ! zagy az alany BMI-je 3 25*29 tmomnányhan va®, Ő, Az L igénypont szeemtj e jjMs, %mW' *®?#M iartaltttszza a IldMzlkplÖ vagy szivfettkéip őzikéi mérését. id. Az I. Igénypont szerinti eljárás, ahol a BNF szint és az oldható ST2 szint vért, plazmát vagy szérumot tartalmazó biológiai mintában vannak detektál«».
HUE12152464A 2006-05-01 2007-05-01 Cardiovascularis betegség diagnózisa HUE028594T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79691206P 2006-05-01 2006-05-01

Publications (1)

Publication Number Publication Date
HUE028594T2 true HUE028594T2 (hu) 2016-12-28

Family

ID=38668487

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12152464A HUE028594T2 (hu) 2006-05-01 2007-05-01 Cardiovascularis betegség diagnózisa

Country Status (13)

Country Link
US (2) US10203339B2 (hu)
EP (3) EP2021796B1 (hu)
JP (5) JP5377289B2 (hu)
AT (1) ATE545032T1 (hu)
AU (1) AU2007248160B2 (hu)
CA (1) CA2650963C (hu)
DK (2) DK2482078T3 (hu)
ES (2) ES2566169T3 (hu)
HU (1) HUE028594T2 (hu)
PL (2) PL2482078T3 (hu)
PT (1) PT2021796E (hu)
SI (1) SI2482078T1 (hu)
WO (1) WO2007130962A2 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
US7998683B2 (en) 2006-04-24 2011-08-16 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PT2019965E (pt) * 2006-05-02 2015-08-28 Critical Care Diagnostics Inc Diagnóstico diferencial entre doença pulmonar e cardiovascular
ES2663662T3 (es) 2008-01-18 2018-04-16 President And Fellows Of Harvard College Métodos para detectar distintivos de enfermedades o afecciones en fluidos corporales
WO2009129454A2 (en) * 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
JP2011530705A (ja) * 2008-08-13 2011-12-22 エフ．ホフマン−ラ ロシュ アーゲー 肺塞栓症のためのＤダイマー、トロポニン、ＮＴ−ｐｒｏＢＮＰ
EP2336740B1 (en) * 2009-12-10 2014-02-12 Emhart Glass S.A. Method and system for monitoring a glass container forming process
US9671357B2 (en) 2009-12-10 2017-06-06 Emhardt Glass S.A. System and method for monitoring hot glass containers to enhance their quality and control the forming process
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130184178A1 (en) 2010-07-23 2013-07-18 President And Fellows Of Harvard College Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
WO2012012709A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2012025633A1 (en) * 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
BR112014001283A2 (pt) 2011-07-18 2017-02-21 Critical Care Diagnostics Inc métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
WO2013022760A1 (en) * 2011-08-05 2013-02-14 Alere San Diego, Inc. Methods and compositions for monitoring heart failure
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
SG10201610537VA (en) 2012-06-15 2017-02-27 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
RU2683026C2 (ru) 2012-08-16 2019-03-26 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
CN104737170A (zh) * 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
EP2931060B1 (en) * 2012-12-14 2017-09-06 Hill's Pet Nutrition, Inc. Anti-aging foods for companion animals
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和***
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012A (en) * 1843-03-21 Machine fob
US4004A (en) * 1845-04-16 Wooden bbidge
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
EP0963205A4 (en) 1996-08-23 2002-10-02 Human Genome Sciences Inc T1 RECEPTOR TYPE LIGAND II
CA2282401A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
PT1003501E (pt) 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
US6210976B1 (en) 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
DK1016867T3 (da) 1997-09-11 2006-05-22 Shionogi & Co Fremgangsmåde til immunassay af BNP
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) * 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
WO2002016416A2 (en) 2000-08-22 2002-02-28 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of cardiovascular conditions
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
ATE458199T1 (de) * 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
WO2003100000A2 (en) 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
WO2004046722A2 (de) * 2002-11-16 2004-06-03 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20050250156A1 (en) 2003-10-31 2005-11-10 Shebuski Ronald J Detection of acute myocardial infarction biomarkers
EP2386657B1 (en) 2003-11-26 2014-01-08 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1986012B1 (en) 2005-01-24 2012-06-06 F. Hoffmann-La Roche AG The use of Bnp-type peptides for assessing the risk of suffering from heart failure as a consequence of volume overload
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
US7998683B2 (en) 2006-04-24 2011-08-16 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2021799B1 (en) 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PT2019965E (pt) 2006-05-02 2015-08-28 Critical Care Diagnostics Inc Diagnóstico diferencial entre doença pulmonar e cardiovascular
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
EP2158330A2 (en) 2007-05-11 2010-03-03 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
WO2009129454A2 (en) 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
CN102317790B (zh) 2008-11-11 2014-12-10 B.R.A.H.M.S有限公司 Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用
WO2011060361A1 (en) 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
BR112014001283A2 (pt) 2011-07-18 2017-02-21 Critical Care Diagnostics Inc métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
RU2683026C2 (ru) 2012-08-16 2019-03-26 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和***
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
US20100009356A1 (en) 2010-01-14
EP2021796A4 (en) 2009-10-28
JP6008933B2 (ja) 2016-10-19
JP5377289B2 (ja) 2013-12-25
CA2650963A1 (en) 2007-11-15
EP2021796A2 (en) 2009-02-11
PT2021796E (pt) 2012-04-19
ES2566169T3 (es) 2016-04-11
PL2021796T3 (pl) 2012-07-31
WO2007130962A3 (en) 2008-09-04
EP2482078B1 (en) 2016-02-03
WO2007130962A2 (en) 2007-11-15
EP2021796B1 (en) 2012-02-08
JP2012163572A (ja) 2012-08-30
JP6470717B2 (ja) 2019-02-13
JP2016218084A (ja) 2016-12-22
JP5467120B2 (ja) 2014-04-09
ATE545032T1 (de) 2012-02-15
PL2482078T3 (pl) 2016-08-31
JP2015064384A (ja) 2015-04-09
DK2021796T3 (da) 2012-05-29
EP3059594A1 (en) 2016-08-24
CA2650963C (en) 2020-09-15
JP5676789B2 (ja) 2015-02-25
EP2482078A1 (en) 2012-08-01
US20190120852A1 (en) 2019-04-25
JP2009535649A (ja) 2009-10-01
US10203339B2 (en) 2019-02-12
SI2482078T1 (sl) 2016-05-31
DK2482078T3 (en) 2016-05-02
JP2014095724A (ja) 2014-05-22
AU2007248160B2 (en) 2011-03-24
ES2380711T3 (es) 2012-05-17
AU2007248160A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
JP6470717B2 (ja) 心血管疾患の診断方法
EP2021799B1 (en) Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2019965T3 (en) DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
WO2009040133A1 (en) Osteopontin as novel prognostic biomarker for heart failure
JP2021170021A (ja) 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法
AU2016201172B2 (en) Diagnosis of cardiovascular disease
WO2022221264A1 (en) Methods and compositions for analysis of acute kidney injury